

1 Gut microbiome alterations precede graft rejection in kidney transplantation patients

2 Johannes Holle^{1,2,3,4*}, Rosa Reitmeir^{2,3,4*}, Felix Behrens^{1,2,3,4}, Dharmesh Singh^{5,6}, Daniela Schindler⁷,
3 Olena Potapenko^{2,4}, Victoria McParland^{2,4}, Harithaa Anandakumar^{2,3,4}, Nele Kanzelmeyer^{8,9}, Claudia
4 Sommerer^{10,11}, Steffen Hartleif^{1,2,13}, Joachim Andassy^{6,14}, Uwe Heemann^{6,15}, Michael Neuenhahn^{5,6},
5 Sofia K. Forslund-Startceva^{2,3,4}, Markus Gerhard^{5,6}, Jun Oh¹⁶, Nicola Wilck^{2,3,4,17,#}, Ulrike Löber^{2,3,4,#},
6 Hendrik Bartolomaeus^{2,3,4,6#}, and members of the German Center of Infection Research Transplant
7 Cohort

8 ¹Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité –
9 Universitätsmedizin Berlin, Berlin, Germany.

10 ²Experimental and Clinical Research Center, a cooperation of Charité – Universitätsmedizin Berlin
11 and Max Delbrück Center for Molecular Medicine, Berlin, Germany.

12 ³German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.

13 ⁴Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

14 ⁵Department of Preclinical Medicine, Institute for Medical Microbiology, Immunology and Hygiene,
15 Technical University of Munich (TUM), TUM School of Medicine and Health, Munich, Germany

16 ⁶German Center for Infection Research (DZIF), Partner Site München, Germany

17 ⁷German Center for Infection Research (DZIF), Partner Site Braunschweig, Germany

18 ⁸Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Children's
19 Hospital, Hannover, Germany

20 ⁹German Center for Infection Research (DZIF), Partner Site Hannover, Germany

21 ¹⁰Department of Nephrology, University of Heidelberg, Heidelberg, Germany

22 ¹¹German Center for Infection Research (DZIF), Partner Site Heidelberg, Germany

23 ¹²Paediatric Gastroenterology and Hepatology, University Children's Hospital Tübingen, Tübingen,
24 Germany

25 ¹³German Center for Infection Research (DZIF), Partner Site Tübingen, Germany

26 ¹⁴Klinik für Allgemeine-, Viszeral-, und Transplantationschirurgie, Klinikum der Universität München,
27 Munich, Germany

28 ¹⁵Department of Nephrology, Technical University of Munich, Munich, Germany

29 ¹⁶Department of Pediatric Nephrology, University Children's Hospital, University Medical Center
30 Hamburg-Eppendorf, Hamburg, Germany

31 ¹⁷Department of Nephrology and Medical Intensive Care, Charité – Universitätsmedizin Berlin, Berlin,
32 Germany

33 *shared contribution

34 #shared last authorship

35

36 Correspondence to:

37 Johannes Holle, MD

38 Experimental and Clinical Research Center (ECRC)

39 Charité – Universitätsmedizin Berlin

40 Lindenberger Weg 80

41 13125 Berlin

42 Germany

43 Mail: johannes-benjamin.holle@charite.de

44 **Abstract**

45 Background: Kidney transplantation (KT) is the optimal treatment for end-stage kidney disease, with
46 graft survival critically affected by the recipient's immune response. The role of the gut microbiome
47 in modulating this immune response remains underexplored. Our study investigates how
48 microbiome alterations might associate with allograft rejection.

49 Methods: We analyzed existing biomaterials of a multicenter prospective study involving 217 KT
50 recipients and 28 kidney donors from the German Center for Infection Research. Changes in the gut
51 microbiome were analyzed using 16S rRNA gene amplicon sequencing and functional predictions
52 (PICRUSt2) and quantitative PCRs for the production potential of propionate and butyrate.
53 Propensity score matching was utilized to compare patients who experienced graft rejection with
54 those who did not.

55 Results: The gut microbiome showed gradual recovery post-KT, marked by an increase of Shannon
56 diversity and SCFA-producing bacterial taxa. However, prior to graft rejection, significant alterations
57 were noted in microbiome composition, characterized by a decrease in microbial diversity and SCFA-
58 producing taxa. Post-rejection analysis revealed normalization of these microbiome features.
59 Functional analysis highlighted a decreased potential for SCFA production in patients prior to
60 rejection. Comparison to published microbiome signatures from chronic kidney disease (CKD)
61 patients demonstrated a partial overlap of the microbiome alterations preceding graft rejection with
62 the alterations typically found in CKD.

63 Conclusions: Our findings suggest that alterations in the gut microbiome composition and function
64 may precede and influence KT rejection, suggesting potential for use as biomarker and early
65 therapeutic microbiome-targeting interventions to improve transplant outcomes.

66

67 **Key points**

- 68 - CKD-related microbiome alterations recover over time after transplantation mirroring CKD-
69 to-health transition
- 70 - Microbiome alterations with lowered production potential of short-chain fatty acids precede
71 graft rejection, likely influencing graft immunity
- 72 - The persistence of CKD-associated microbiome characteristics in rejection patients opens
73 avenues for innovative treatment strategies.

74

75 1. Introduction

76 Kidney transplantation (KT) represents the best treatment option for patients with advanced kidney
77 failure (CKD G5)¹. Despite ongoing efforts to prevent the progression of CKD and related
78 comorbidities, successful KT and graft survival, especially prevention of graft rejection, are of
79 outmost importance. Graft rejection is the medium- and long-term complication with highest impact
80 on graft and subsequently recipient survival². Whether a patient experiences acute or chronic graft
81 rejection or not is, according to the current scientific understanding, largely dependent on immune
82 mechanisms, the modifiers of which still remain poorly understood³.

83 Of late, the gut microbiome gained considerable attention as key modulator of the immune system
84 in both healthy and disease conditions⁴. Microbiota, their metabolites and associated molecules
85 interact with numerous host organs including mucosa-associated and systemic immune cells and
86 thereby shape host immunity and inflammation⁵. Patients with CKD exhibit marked alterations to
87 their gut microbiome composition and subsequent dysregulation of metabolite abundance⁶. In
88 particular, a switch from saccharolytic to proteolytic fermentation is observed⁷. On one hand this
89 leads to lower intestinal and systemic concentrations of short-chain fatty acids (SCFA)⁸, previously
90 identified as inducers of regulatory immunity⁹. On the other hand, increased levels of pro-
91 inflammatory metabolites, such as tryptophan-derived indoxyl sulfate, are observed⁸.

92 After KT, CKD-related microbiome alterations can partially persist, presumably by contribution of
93 additional factors such as immunosuppression¹⁰, and are associated with clinical events like post-
94 transplant diarrhea^{11,12}. A recent study rigorously demonstrated an association between lower gut
95 microbial diversity in patients with solid organ transplantation and increased overall mortality¹³. A
96 growing body of evidence implicates the gut microbiota in alloimmunity and graft rejection. Germ-
97 free mice and mice treated with antibiotics show prolonged skin graft survival compared to
98 conventional mice, suggesting that alloimmunity is modulated by microbiota¹⁴. Furthermore, recent
99 studies indicate that gut microbes directly affect immune-regulatory cells (regulatory T cells, Th17

100 cells)^{15,16}, with SCFA playing a central role in this relationship¹⁷. Studies in mice showed that SCFA
101 supplementation mediates donor-specific tolerance to kidney allograft through induction of Foxp3⁺
102 regulatory T-cells¹⁸. Finally, human interventional studies are underway, aiming to improve CKD-
103 associated microbiome alterations by prebiotic inulin supplementation¹⁹ or at improving immune
104 regulation by supplementation of regulatory T cells²⁰.

105 In this study, we analyzed longitudinal changes in the composition and function of the gut
106 microbiome of KT recipients enrolled in the transplant cohort (Tx cohort) of the German Center of
107 Infectious Diseases (DZIF)²¹ and connect them with the clinical outcomes, specifically graft survival
108 and rejection. In a propensity score-matched subcohort we identify microbial alterations preceding
109 graft rejections and transplant dysfunction.

110

111 **2. Materials and methods**

112 **Study Population and Design**

113 All patients analyzed in this study were part of the Tx cohort of the DZIF, which is a multicenter
114 prospective cohort study conducted at four German transplant centers (University Hospitals in
115 Heidelberg, Munich (Technical University and Ludwig Maximilian University) and Tübingen)²¹.
116 Together, these centers cover over 20% of solid organ transplants in Germany²² providing a
117 representative picture of post-transplant course in Germany.

118 For the present study, we analyzed data from all kidney allograft recipients who consented to
119 participate and received a kidney transplant between July 2014 and July 2021. Samples were
120 collected between March 2017 and September 2021. Patients receiving multi-organ transplantation
121 or patients who underwent previous solid organ transplantation were excluded (Supplemental
122 Figure 1). Moreover, participants without fecal samples were excluded from our analysis. Ethics
123 approval was obtained from all participating centers (Heidelberg #S-585/2013, TU Munich #5926/13,
124 LMU Munich #380-15, Tübingen #327/2014BO1), and all participants provided written informed
125 consent. The experimental analysis of fecal samples, including metadata analysis, was approved by
126 the ethics board of Charité – Universitätsmedizin Berlin (EA2/208/21).

127 The study design, including biomaterial collection, was described previously²¹. Fecal samples were
128 collected using DNA stabilizing buffer (STRATEC). Study visits were performed immediately before
129 KT, at months 3, 6, 9, and 12 after KT and when infections or rejection events were detected. Clinical
130 and laboratory data were collected at each study visit.

131 **Standard of care treatment**

132 The patients received a standard triple-drug combination of immunosuppressants (comprising a
133 calcineurin inhibitor, mycophenolate (MPA), and corticosteroids), initially frequently together with

134 an interleukin 2 receptor antagonist (basiliximab). The prophylaxis and surveillance strategy for
135 infectious complications was suggested to be performed according to KDIGO 2009 guidelines²³,
136 including antiviral prophylaxis with valganciclovir for patients at high risk for cytomegalovirus (CMV)
137 infections, trimethoprim-sulfamethoxazole prophylaxis against *Pneumocystis jirovecii* and urinary
138 tract infections, *Candida* prophylaxis with oral nystatin or amphotericin B.

139 **Matching of rejection/non-rejection patients**

140 We conducted our analysis using R (4.3.2), employing MatchIt (4.5.5)²⁴ package for sample matching.
141 Patients with histologically proven rejection events were assessed (T cell-mediated rejection (TCMR,
142 Banff category 4) and Borderline (Suspicious) for acute TCMR (Banff category 3))²⁵, if the rejection
143 occurred within five years after KT and fecal sampling was obtained before the rejection event (time
144 frame 781 days before the rejection till 3 days after rejection). Patients without sample before
145 rejection and those with-mediated rejection (ABMR) were excluded from the analyses, yielding 33
146 patients with rejection events. Stool samples taken closest before the rejection event were selected
147 for analyses. Control samples were matched based on the absence of rejection and similar baseline
148 characteristics, using nearest neighbour matching with a 2:1 ratio, matching two controls for each
149 rejection case based on the factors primary condition, donor type, time since transplantation, age,
150 and gender. Of the selected 99 patients, one rejection patient was excluded because of primary graft
151 dysfunction (patient still required dialysis three months after KT) and six patients without rejection
152 were excluded because of sustained poor kidney function (plasma creatinine > 2.5 mg/dL).

153 Detailed information on clinical data preparation, sample collection and processing, 16S amplicon
154 sequencing, SCFA production gene targeting assay (qPCR) and re-analysis of the CKD dataset²⁶ can be
155 found in the online only supplemental material.

156 **Statistical Analysis**

157 Continuous variables were expressed as medians and interquartile ranges (IQRs). Categorical
158 variables were presented as numbers and percentages. All statistical analyses were conducted using
159 R (4.2.3).

160 Analysis of alpha diversity and multivariate analysis: Alpha diversity and multivariate analysis were
161 performed on OTU level on the non-rarefied data. Different metrics for alpha Diversities were
162 calculated using the R-package microbiome (v.1.12.0)²⁷. Differences in alpha Diversity were tested
163 using Wilcoxon rank sum test on a significance level of 0.05. For multivariate analysis, Bray-Curtis
164 indices were obtained using the R-package phyloseq (v.1.34.0)²⁸ and tested via PERMANOVA using
165 adonis2 of the R-package vegan (v.2.6-4)²⁹.

166 Cross-sectional comparison: For the association analysis, the R-package metadefoundR (v.0.2.8)
167 was used³⁰. The testing was performed on the rarefied data (minimum read count 10270 reads) and
168 all taxonomic levels with a minimum prevalence of 0.1. Wilcoxon rank sum test was performed for
169 binary variables, Spearman's correlation for continuous variables, and Kruskal-Wallis test for ordinal
170 variables. The obtained p-values were adjusted using the Benjamini-Hochberg false discovery rate
171 (FDR) correction. In total, 65 clinical variables were considered as confounding factors (Supplemental
172 Table 1). An association was considered statistically significant when $FDR < 0.1$.

173 For individual comparisons of clinical and qPCR parameters, Mann-Whitney *U* test was performed
174 and $p < 0.05$ was considered statistically significant.

175 Longitudinal Analysis: For the longitudinal analysis, LongDat (v.1.1.2)³¹ was used, building negative
176 binomial generalized linear mixed models over time after KT, controlling for sample origin by a
177 random intercept. The models were built on rarefied data with default filtering³¹. FDR was controlled
178 by Benjamini-Hochberg procedure. A change in abundance over time as considered statistically
179 significant when $FDR < 0.1$.

180 Diversity parameters during different periods before and after KT were compared using Mann-
181 Whitney *U* test and $p < 0.05$ was considered statistically significant.

182 Functional capacity prediction using Picrust2: PICRUSt2³² obtained abundances of the KEGG
183 orthologs (KOs) were z-score scaled and tested for significance with a linear model correcting for age
184 and sex (Benjamini-Hochberg-corrected FDR < 0.05). All significant KOs were mapped to the
185 corresponding GOMixer modules³³ and tested for group difference using Wilcoxon rank sum test
186 with a significance level of FDR < 0.05 using the online tools of GOMixer.
187

188 3. Results

189 Gut microbiota composition recovers gradually post-kidney transplantation

190 We used medical data and fecal samples from the DZIF Transplant Cohort. This multi-center cohort
191 consists of nearly 2400 patients undergoing solid organ transplantation. Here, we focused on fecal
192 samples from patients undergoing KT (n=562 samples, from n= 245 individuals), including kidney
193 donors (n=28) and, if available, pre-transplantation samples (n=26). Baseline characteristics of the
194 cohort can be found in Table 1.

195 We analyzed the microbiome composition using 16S rRNA gene amplicon sequencing. For
196 longitudinal analysis post-KT, samples were grouped according to sampling time, namely 0-3 months
197 (n=69), 3-12 months (n=226) 12-24 months (n=94), 24-36 (n=66), and over 36 months (n=53) post-KT
198 (Supplemental Figure 1). Principal Coordinates Analysis (PCoA) of Bray-Curtis dissimilarity revealed
199 an overall stable microbiome composition post-KT, while the healthy donors and pre-KT groups
200 differed (Fig 1A). While the detected number of operational taxonomic units (OTU, a proxy for
201 bacterial taxa) was mostly stable post-transplantation (Fig 1B), we observed significant shifts in the
202 alpha diversity as quantified by Shannon diversity index (Fig 1C). While Shannon diversity decreased
203 before and in the first year after transplantation, it gradually increased again over time post-KT. We
204 observed a similar trend for Simpson evenness, although most comparisons were not significant (Fig
205 1D).

206 We performed longitudinal analysis using LongDat³¹ to identify bacterial taxa regulated over time
207 post-KT. Post-transplantation, typical SCFA-producing genera like *Coprococcus*³⁴, *Lachnospiraceae*³⁵,
208 *Roseburia*³⁶, *Faecalibacteria*³⁷ and *Ruminococcus* torques group³⁸ increased significantly over time
209 (Fig 1E), suggesting an improvement of CKD-associated microbiome alterations, specifically the
210 impaired production of SCFA as one of its hallmarks^{6,8}. Furthermore, we observed a decrease in
211 *Streptococcus*, which was recently linked with subclinical atherosclerosis³⁹ (Fig 1E). In summary, our

212 analysis demonstrates a dynamic regeneration of the microbiome over time after KT towards a more
213 physiological state after three years or more post-KT.

214 **Kidney transplant rejection profoundly impacts microbiome composition**

215 Since we observed dynamic microbiome changes over time in KT patients, we aimed to understand
216 how transplant rejection events influence this process and, vice versa, how microbiome alterations
217 may impact allograft immunity. Therefore, we identified fecal samples (n= 157) from patients (n= 76)
218 with biopsy-proven rejection events at any timepoint after KT (Table 1). PCoA of Bray-Curtis
219 dissimilarity showed a distinct clustering of patients experiencing graft rejection compared to KT
220 patients with no reported rejection (Fig 1F). While the number of detected OTUs was constant over
221 time (Supplemental Figure 2), Shannon diversity and Simpson evenness were reduced during the
222 first year post-transplantation in rejection patients (Fig 1G-H), which was co-incident with the
223 allograft rejection. Lastly, we performed univariate analyses on genus level using
224 metadeconfoundR³⁰. Corresponding to the altered composition in the multivariate analysis, we
225 found a large number of differentially abundant genera (Supplemental Figure 3). Interestingly, the
226 majority of observed effects related to rejection showed a contrasting trend in correlation with the
227 duration between sampling and kidney transplant rejection event (Fig S3). This correlation indicates
228 either microbiome alteration preceding the rejection event, changes in the microbiome post-
229 rejection, or both. Of note, our analysis indicates that many effects were confounded by patient age
230 and distance to KT.

231 Taken together, patients who experience KT rejection have an altered gut microbiome composition.
232 We hypothesize, that these changes might precede transplant rejection, as the alterations associate
233 with the time between sampling and KT rejection event.

234 **Microbiome alterations precede kidney transplant rejection**

235 To overcome the inherent limitations of the cohort that is unequally distributed age and distance to
236 KT of rejection and non-rejection patients and to further understand which alterations to the
237 microbiome precede KT rejection, we performed propensity score matching of patients with
238 available fecal samples before KT rejection to patients without KT rejection. Matched pre-rejection
239 and non-rejection groups were comparable in age, sex, donor type, underlying CKD disease category
240 and time between KT and sample (Supplemental Figure 4). Baseline characteristics of this subgroup
241 of patients are shown in Table 2.

242 Rejection patients exhibited impaired renal function as compared to non-rejection patients as
243 displayed by an increase in plasma creatinine within the first year post-KT, which remained the case
244 during follow-up (Fig 2A). This corresponds to most rejections in our cohort occurring within one
245 year post-KT (Table 1 and 2). However, both rejection and normal progress patients reached a
246 similar minimal creatinine as well as time to minimal creatinine (Fig 2B), indicating that initial graft
247 function was comparable between both groups. After the rejection event, kidney transplants
248 showed sustained graft dysfunction as indicated by higher minimal detected creatinine values after
249 their rejection event as well as higher last recorded creatinine (Fig 2B). Of note, HLA mismatch
250 grade, rate of ABO incompatibility and delayed graft function were comparable between both groups
251 (Table 2).

252 Microbiome analysis indicated alterations prior to the rejection event. Pre-rejection microbiome
253 composition was characterized by a distinct composition indicated by different clustering in the
254 PCoA of Bray-Curtis dissimilarity (Fig 2C), and lower alpha-diversity, reaching significance for
255 Simpson evenness (Fig 2D). Patients who rejected the transplanted kidney had lower level of known
256 SCFA producers on genus level, like *Blautia*, *Clostridia*, or *Ruminococcus torques* group³⁸.
257 Interestingly, we observed an increase in bacteria typically found in CKD patients, like
258 *Fusobacterium*⁸, and disease-associated genera⁴⁰, such as *Streptococcus*³⁹ and *Porphyromonas*⁴¹ (Fig
259 2E).

260 Despite our efforts to closely match the rejection and non-rejection groups, a higher rate of viral
261 infections was observed in the rejection group. We therefore carefully assessed the use of
262 immunosuppressants and anti-infective medication (Supplemental Figures 5-7), pointing out two
263 main differences, namely a lower number of patients on MPA at sampling date – likely due to the
264 viral complications – and a lower number of patients with basiliximab for induction in the rejection
265 group. Multivariate analysis revealed no difference in microbiome composition in rejection patients
266 with or without basiliximab induction (Supplemental Figure 8), but MPA withdrawal showed a non-
267 significant shift in microbiome composition. Therefore, we performed the genus level differential
268 abundance analysis, including and excluding patients with MPA discontinuation, which closely
269 correlated ($R= 0.98$, $p< 0.001$) (Supplemental Figure 9). This indicates that the observed differences
270 were independent of basiliximab induction or MPA discontinuation, respectively.

271 **Lower SCFA production potential characterizes the pre-rejection microbiome**

272 Metabolites produced by microbiota are known to influence and modulate host immune responses.
273 To identify potential candidates, we analyzed functional capacities, predicted from our taxonomic
274 data using PICRUSt2³², identifying functional pathways in the significantly altered KOs using
275 GOMixer^{33,42}. We observed an overall clustering of rejection and non-rejection patients in the PCA
276 (Fig 3A). We found an enrichment in proteolytic fermentation, reactive nitrogen and oxygen species,
277 and ammonia pathways in the rejection group (Fig 3B, C). Conversely, overall sugar and
278 polysaccharide utilization and mucus degradation were enriched in microbiomes from non-rejection
279 controls (Fig 3B, C). Matching to the reduced number of SCFA-producing genera we found a
280 reduction in butyrate and acetate fermentation pathways (Fig 3B, C), again highlighting the
281 reduction of SCFA production in stool samples preceding KT rejection (Fig 3B, C). Since SCFA and
282 regulatory immune functions are closely linked, we aimed to confirm the reduction of SCFA
283 production using qPCR measuring key enzymes for butyrate and propionate production. Overall, we
284 found a significant reduction of butyryl-CoA:acetate CoA-transferase (*but*), a key enzyme for

285 butyrate production, and methylmalonyl-CoA decarboxylase (*mmdA*), a key enzyme for propionate
286 production (Fig 4A, B). Another central enzyme for butyrate synthesis, butyryl-CoA dehydrogenase
287 (*bcd*), was reduced without reaching significance (Fig 4A, B). Taken together, a key feature of the gut
288 microbiome in samples from patients preceding KT rejection is a marked reduction of the potential
289 to produce SCFA.

290 **Microbiome alterations normalize post-rejection**

291 As our initial analysis indicated a potential shift post-rejection, we analyzed longitudinal samples
292 from our matched cohort within a timeframe of 90 to 1000 days after the first sample (n=21
293 rejection and n=54 non-rejection patients). PCoA using Bray-Curtis dissimilarity shows that the
294 microbiome composition becomes more similar to the non-rejection control group in post-rejection
295 samples (Fig 5A). Over a similar time frame the microbiome composition of non-rejection controls
296 was stable. The same trend could be observed for the number of detected OTUs, Shannon diversity
297 and Simpson evenness (Fig 5B). Next, we analyzed microbiome alterations post-rejection on genus
298 level (Fig 5C). While the non-rejection control showed no significant alterations, most genera
299 dysregulated preceding rejection were significantly changed in the opposite direction after the KT
300 rejection event (Fig 5C). Especially known genera of SCFA production like *Blautia* and
301 *Faecalibacterium* increased, while disease-associated genera like *Fusobacterium* and *Streptococcus*
302 decreased (Fig 5D).

303 Taken together, we observe a normalization of the pre-rejection microbiome towards the normal KT
304 signature in a longitudinal follow-up analysis. One could speculate that a lack of normalization of the
305 microbiome favors chronic rejections. Due to insufficient sample size, we could not further test this
306 hypothesis in this study.

307 **The microbiome signature in kidney transplant rejection is a prolonged CKD signature**

308 Lastly, we aimed to contextualize the microbiome alteration preceding KT rejection. We observed a
309 partial overlap with a microbiome features of pediatric CKD patients recently published by us⁸.
310 Therefore, we hypothesized that the microbiome alterations preceding KT rejection in parts reflects
311 a prolonged CKD signature after KT. Therefore, we re-analyzed a recently published 16S rRNA gene
312 sequencing dataset from CKD patients (n=217) and healthy controls (n=479)²⁶. In line with our
313 hypothesis, the KT rejection signature correlated with the CKD signature in the dataset from Ren et
314 al. (for the 120 common genera, R= 0.19, p= 0.033) (Fig 6A). In particular, the overlap of both
315 datasets also held true for the reduction of important SCFA producers like *Blautia* and
316 *Faecalibacterium*, as well as for the increase in *Streptococcus* and *Fusobacterium*, with the latter not
317 reaching significance in the CKD-HC comparison (Fig 6A, B). Lastly, we performed a targeted analysis
318 of bacterial taxa captured by our *but*, *bcd* and *mmdA* assays. Overall, the abundance of butyrate and
319 propionate producing taxa was lower in CKD patients mirroring the effect we observed in
320 microbiome samples preceding KT rejection (Fig 6C).

321 In aggregate, our data indicate that the pre-rejection signature we observed in our cohort might in
322 part be a sustained CKD signature. Especially the lack of fiber fermenting, SCFA-producing bacteria is
323 a key feature found in both disease states.

324 4. Discussion

325 In the present study, we investigate the gut microbiome in KT recipients and its relationship with
326 allograft rejection. KT remains the best treatment option for patients with advanced and dialysis-
327 dependent CKD, but graft availability is limited. Therefore, the improvement of graft survival and
328 prevention of allograft rejection are paramount. For the first time, we describe compositional and
329 functional differences in the microbiome in a representative cohort of 217 transplant patients with
330 and without rejection, which are of potential prognostic and therapeutic value.

331 Our analysis of longitudinally collected fecal samples unveils a dynamic trajectory of microbiome
332 recovery post KT, which undertakes a gradual shift towards a more stable and healthier microbiota
333 composition⁴⁰ over time. This gradual process is marked by the enrichment of bacterial taxa
334 associated with short-chain fatty acid (SCFA) production (such as *Roseburia*, *Faecalibacterium*), and a
335 loss of disease-associated taxa (such as *Streptococcus*). These regenerative microbiome shifts post
336 KT are significantly perturbed in the case of graft rejection. Preceding the rejection event, we
337 observed profound alterations in microbiome composition, characterized by a diminished diversity
338 and underrepresentation of SCFA-producing bacterial populations. Notably, these alterations tend to
339 normalize post KT rejection events. We consider these observations to be of potential functional
340 relevance for allograft immunity due to the known immunomodulatory properties of SCFA
341 reference^{9,17}. Although our study was not designed to show causality, our results suggest that the
342 microbiome is an important modulator of immunologic events after KT - an observation that may
343 also have prognostic significance for the prevention of KT rejection and graft survival.

344 The observed gradual normalization of the microbiome composition after KT aligns for several
345 bacterial taxa the normalization of known alterations in the gut microbiome of CKD patients. The gut
346 microbiome of CKD patients is relatively well investigated. It is characterized by a lower diversity and
347 a shift in metabolic output^{6,8,26,43}. While the production of SCFA metabolites, recognized for their
348 anti-inflammatory effects⁹, is reduced⁸, we and others have observed an increase in the production

349 of microbiome-derived uremic toxins like TMA⁴⁴, p-cresols⁴⁵ and indoles^{8,46}. Of note, the microbiome
350 of CKD patients is characterized by an increase of bacterial taxa frequently linked to health-to-
351 disease transition in large representative metagenomic studies^{40,47}. In the present study, we observe
352 a decrease of known pathogenic bacteria and increase in beneficial commensals over the course of
353 more than three years post KT. Thus, the observed changes are reminiscent of a CKD-to-health
354 transition in the microbiome. Dysbiotic microbiome states in KT patients have been described by
355 others^{10,13}. Swarte and colleagues demonstrated that lower gut microbial diversity in kidney and liver
356 transplant recipients is associated with an increased overall mortality¹³. As graft survival is the most
357 important predictor of overall medium- and long-term survival after KT², we hypothesize that gut
358 bacterial diversity may also be important for graft survival.

359 We demonstrate that alterations of the gut microbiome, including a reduced microbial diversity, and
360 alterations in the abundance of more than 50 bacterial taxa, occur before graft rejection.
361 Microbiome composition preceding graft rejection was characterized by several typical disease-
362 associated species. Most prominent and similar to the analyzed CKD signature, we found an increase
363 in *Streptococcus*. *Streptococcus spp.* were recently correlated to subclinical atherosclerotic lesions in
364 a cohort of nearly 9000 patients³⁹. Another genus found to be upregulated in rejection and CKD
365 (although not reaching significance in the cohort we reanalyzed²⁶ as compared to other studies⁸) was
366 *Fusobacterium*. *Fusobacterium nucleatum* was recently described as a driver of uremic toxins
367 production and CKD progression⁴³, again underscoring the notion of a prolonged CKD signature in
368 the microbiome as a potential risk factor for graft rejection. We and others have shown that SCFA
369 are relevant bacterial metabolites for immune homeostasis in CKD as well as for other chronic
370 diseases^{8,17,48-50}. Using computational prediction of functional microbiome properties (PICRUSt2³²),
371 we show a significantly reduced potential of the gut microbiome to produce SCFA. PICRUSt2 predicts
372 microbiome functions such as SCFA production based on the available genomic data and the inferred
373 presence of genes from closely related taxa³². PICRUSt accuracy significantly decreases for microbes
374 with fewer close relatives in reference databases⁵¹. Acknowledging this limitation, we validated the

375 regulation of several key enzymes for SCFA synthesis using gene targeting qPCR assays. Therefore,
376 the microbiome may be functionally implied in the development of graft rejection.

377 A recent meta-analysis concluded that immune cell therapies, including transfer of regulatory T cells
378 (Treg), are a useful approach to reduce immunosuppression during KT²⁰. The findings of our study
379 and others suggest that SCFA warrant scientific attention as Treg-modulating bacterial metabolites.
380 SCFA have been shown to influence the function and differentiation of Treg both through GPR
381 signaling and HDAC inhibition^{9,52}. Experimental transplantation models demonstrate the efficacy of
382 SCFA treatments through induction of Treg. Kidney transplants showed a prolonged survival in
383 animals fed a high fiber diet or directly the SCFA acetate⁵³. Thus, the rapid attainment of a healthy
384 SCFA production potential could be relevant for Treg function and the prevention of rejection events
385 as well as other comorbidities found after KT⁵⁴.

386 Two recent smaller studies similarly suggest alterations of the microbiome in patients with acute
387 rejection (n=3 patients, including both TCMR and antibody-mediated rejection)⁵⁵ or patients with
388 antibody-mediated rejection (n=24)⁵⁶. While the first study is severely limited by its low sample size,
389 the second study – albeit focusing on ABMR compared to our focus on TCMR – described on a broad
390 scale similar features like a reduced alpha diversity. Of note, the observed microbiome alterations in
391 our study preceding rejection events normalized during longitudinal follow-up. Future studies are
392 needed to investigate whether persistent microbiome alterations influence the risk for chronic
393 rejection.

394 The circumstance that fecal samples were not consistently available from all patients at all
395 timepoints in our multi-center cohort limits the validity of our study. However, in non-rejection
396 patients a minimum sample number of two stool samples per patient was not undercut, which
397 enabled the longitudinal character of our study. Despite this, our findings clearly indicate a gradual
398 shift towards a more stable microbiome state post-transplantation. A further limitation is the lack of
399 metabolomic measurements in our study, which we replaced with specific quantifications of the

400 microbial enzyme composition. Finally, the study design does not allow causal statements on the
401 mechanistic significance of microbiome changes for rejection. However, our conclusions regarding
402 the role of SCFA for Treg function are broadly based and supported by published experimental data.
403 Future studies should consider functional data on immune cells and their relationship to microbiome
404 and rejection to validate our conclusions.

405 Taken together, we demonstrate a disrupted microbiome recovery post KT as a novel modifying
406 factor in graft survival. This is to our knowledge the first study indicating that microbiome alterations
407 and perturbation of microbial metabolism precede graft rejection. More studies are needed to
408 decipher the interaction of SCFA and Treg in KT patients and to test the potential of microbiome-
409 targeting interventions before and after KT to improve long term graft survival.

410

411 **Funding**

412 This study was conducted with resources provided by the DZIF transplant cohort e.V.
413 (<https://www.dzif.de/en/working-group/transplant-cohort>), support code TTU 07.701, and
414 additional DZIF funding under TTU 07.916 to M. Gerhard, D. Schinderl and J. Holle. J. Holle was
415 supported by the Else Kröner-Fresenius Stiftung (2023_EKEA.127). N. Wilck was supported by the
416 European Research Council under the European Union's Horizon 2020 research and innovation
417 program grant 852796 and by the Corona Foundation in the German Stifterverband. H.
418 Bartolomaeus and N. Wilck were supported by the BMBF, Foerderkennzeichen 01EJ2202A (TAhRget
419 consortium).

420 **Acknowledgement**

421 We thank the members of the German Center of Infection Research Transplant Cohort, in particular
422 the members of the executive board and the scientific steering committee: Dr. Susanne Delecluse,
423 Dr. Tina Ganzenmüller, Dr. Bärbel Fösel, Dr. Caroline Klett-Tammen, Dr. Thomas F. Schulz, Dr. Uwe
424 Heemann, Dr. Thomas Giese, Dr. Philip Ehlermann, Dr. Rasmus Rivinius, Dr. Uta Merle, Dr. Peter
425 Lang, Dr. Martin Hildebrandt, Dr. Christine S. Falk, Dr. Burkhard Tönshoff, Dr. Anette Melk, Dr.
426 Thomas Illig, Dr. Berit Lange, and Dr. Thomas Iftner.

427 **Data sharing statement**

428 Deidentified metagenomic sequencing data for samples of the Transplant Cohort of the DZIF can be
429 accessed from the European Nucleotide Archive under accession number PRJNA1106540
430 (<https://www.ebi.ac.uk/ena/browser/view/PRJNA1106540>). Access to pseudonymized phenotype
431 data requires approval from the scientific steering committee of the DZIF Transplant cohort. The
432 source code and the summary data underlying all figures used to generate the results for the
433 analysis are available at [https://github.com/rosareitmeir/DZIF-Tx-Cohort-Data-Cleaning-and-](https://github.com/rosareitmeir/DZIF-Tx-Cohort-Data-Cleaning-and-Statistical-Analysis)
434 [Statistical-Analysis](https://github.com/rosareitmeir/DZIF-Tx-Cohort-Data-Cleaning-and-Statistical-Analysis).

436 **Supplemental Material**

437 **Supplemental Figures**

438 **Supplemental Figure 1. Study design.** Flow chart of the study design with inclusion and exclusion of
439 patients and final sample number.

440 **Supplemental Figure 2. Observed OTU in rejection (red) and non-rejection (blue) patients.**
441 Horizontal lines indicate the number of detected OTU, shaded area is the 95% confidence interval.
442 Vertical lines on top of the x-axis indicate rejection events.

443 **Supplemental Figure 3. Impact of rejection state on gut microbiome composition.** Analysis of fecal
444 samples from patients experiencing kidney rejection at any time compared to patients never
445 experiencing graft rejection. Heatmap showing associations of bacterial genera with kidney
446 transplant rejection. Meta-variables with significant association are shown. Stars indicate de-
447 confounded significant associations; grey dots indicate confounded associations. °/*FDR< 0.1,
448 °°/**FDR< 0.01, °°°/**FDR< 0.001.

449 **Supplemental Figure 4: Matching of rejection and non-rejection patients.** Plots indicate
450 metavariabes before (left) and after propensity score matching (right). Grey bars/ histogram
451 indicate non-rejection before (left) and after (right) propensity score matching. Rejection is shown in
452 black.

453 **Supplemental Figure 5: Immunosuppressive treatment at the time of transplantation (A) and at
454 the time of fecal sampling (B).** Fecal samples were analysed from patients before experiencing graft
455 rejection (Rejection, red) and propensity score matched (1:2) controls (normal progress, blue). Bar
456 plots indicate medication at A) transplantation and B) fecal sampling.

457 **Supplemental Figure 6. Tacrolimus plasma levels in matched rejection and non-rejection patients.**
458 A) Tacrolimus plasma levels of n=92 patients (matched cohort) for the time between transplantation
459 and sample collection before rejection event (n=121 data points of 51 patients for non-rejection and
460 51 data points of 23 patients for rejection group). B) Difference of target to actual values of
461 Tacrolimus. Target values have been determined by the respective clinical recommendations after
462 kidney transplantation.

463 **Supplemental Figure 7: Anti-infective medications used between kidney transplantation and fecal
464 sampling.** Anti-infective medication used between kidney transplantation and fecal sampling for the
465 matched cohort (normal progress, blue; rejection, red). Medication used both preventive and
466 therapeutic is shown.

467 **Supplemental Figure 8: Impact of basiliximab induction therapy on the gut microbiome**
468 **composition.** PCoA on Bray-Curtis Dissimilarity of the 16S amplicon sequencing in rejection patients
469 with (brown) and without (orange) basiliximab use during induction. Statistical testing using
470 PERMANOVA shows no difference.

471 **Supplemental Figure 9: Impact of mycophenole (MPA) withdrawal on the gut microbiome**
472 **composition.** A) PCoA on Bray-Curtis Dissimilarity of the 16S amplicon sequencing in rejection
473 patients with (light green) and without (dark green) MPA at fecal sampling. Statistical testing using
474 PERMANOVA shows no difference, although some distinct clustering can be seen. B) Correlation of
475 effect sizes in the whole rejection cohort (x-axis) and the cohort excluding patients with MPA
476 withdrawing (y-axis). Axis shows Cliff's deltas for all detected genera in the gut microbiome.
477 Spearman correlations, individual significances for genera using univariate testing in
478 metadeconfoundR.

479

480 **Supplemental Tables**

481 **Supplemental Table 1:** Clinical variables used for deconfounding of microbiome features

482 **Supplemental Table 2:** Primers used for 16S sequencing.

483 **Supplemental Table 3:** Bacterial species included to the gene targeting assays for butyrate and
484 propionate synthesis and corresponding primer sequences.

485

486 **Tables**

487 **Table 1.** Clinical baseline characteristics total cohort. Kidney transplant (KT) donors, pre-KT CKD
 488 patients and post-KT CKD patients from the transplant cohort of the German Center of Infectious
 489 Diseases (DZIF) were analyzed in this study. Data are presented as median and interquartile range or
 490 absolute values and percentages as appropriate.

	donors	pre-KT	post-KT	N
individuals (N)	28	26	213	
samples	28	26	508	
samples per participant	1	1	2 (2-3)	
age (years)	53 (46-68)	52 (34-60)	54 (40-63)	28, 26, 213
female	20 (71%)	6 (25%)	70 (33%)	28, 24, 211
BMI (kg/m ²)	26.1 (24.0-28.3)	25.1 (21.6-27.3)	24.6 (21.6-28.0)	22, 26, 210
time since KT (days)	NA	NA	294 (148-715)	213
living donor	NA	NA	81 (38%)	212
ABO incompatible KT	NA	NA	18 (9%)	204
rejection	NA	NA	76 (35%)	213
kidney diagnosis				26, 213
cystic	NA	4 (15%)	43 (20%)	
diabetic	NA	2 (8%)	14 (7%)	
glomerular	NA	10 (38%)	71 (33%)	
hereditary/congenital	NA	6 (23%)	25 (12%)	
hypertensive	NA	0	16 (8%)	
other/unknown	NA	4 (15%)	37 (17%)	
tubulointerstitial	NA	0	7 (3%)	
primary graft dysfunction	NA	NA	8 (4%)	209
delayed graft function	NA	NA	38 (18%)	218
in-patient length of stay	NA	NA	19 (14-26)	210

491

492 **Table 2.** Clinical baseline characteristics of the propensity score-matched cohort. Kidney transplant
 493 (KT) recipients from the transplant cohort of the German Center of Infectious Diseases (DZIF) were
 494 analyzed in this study. Samples were obtained after KT from all patients, but before rejection in the
 495 rejection group. Data are presented as median and interquartile range or absolute values and
 496 percentages as appropriate. Primary graft dysfunction: patient still required dialysis three months
 497 after KT. Delayed graft function: patient required one to three dialysis treatments after KT.

	non-rejection	rejection	all	N
individuals (N)	60	32	92	
age (years)	55 (44-63)	58 (47-62)	56 (45-63)	92
female	22 (37%)	11 (34%)	33 (36%)	92
BMI (kg/m ²)	23.4 (20.8-27.6)	24.6 (21.5-27.2)	24.1 (21.1-27.5)	92
sample days after KT	111 (85-175)	114 (84-192)	112 (85-181)	92
rejection days after KT	NA	173 (132-282)	NA	92
living donor	20 (33%)	10 (31%)	30 (33%)	92
ABO incompatible KT	5 (8%)	1 (3%)	6 (7%)	92
HLA mismatches (HLA-A, HLA-B, HLA-DR)	2 (2-3)	3 (2-4)	3 (2-4)	79
primary graft dysfunction	0	0	0	88
delayed graft function	9 (15%)	2 (6%)	11 (12%)	92
in-patient length of stay (days)	19 (14-24)	18 (14-26)	19 (14-24)	91
recipient CMV ⁺	26 (46%)	14 (47%)	40 (46%)	87
recipient EBV ⁺	35 (83%)	18 (90%)	53 (85%)	62
bacterial infections before sample	32	20	52	92
patients with bacterial infection before sample	17 (28%)	20 (34%)	37 (40%)	92
viral infections before sample	12	23	35	92
patients with viral infection before sample	9 (15%)	14 (44%)	23 (25%)	92

498

499

500 **Figure legends**

501 **Figure 1. Longitudinal changes to the gut microbiome after kidney transplantation and impact of**
502 **allograft rejection.** 16S rRNA gene amplicon sequencing from fecal material from kidney
503 transplantation (KT)-related samples from the transplant cohort of the German Center of Infectious
504 Diseases (DZIF). Samples were grouped according to healthy kidney donors, pre-KT, 0-3 months post-
505 KT, 3-12 months, 12-24 months and over 24 months. A) PCoA based on Bray-Curtis dissimilarity.
506 Quantification of the B) Number of detected OTU, C) Shannon diversity, and D) Simpson evenness. E)
507 Cuneiform plot displaying significantly altered bacteria post-transplantation over time. Microbial
508 diversity in kidney transplant recipients with and without graft rejection at any point is shown in F-H.
509 F) Principal Coordinates Analysis (PCoA) based on Bray-Curtis dissimilarity illustrates the distinct
510 clustering of patients who experienced graft rejection (red circles) from those without rejection
511 (blue circles). Red and blue squares mark the respective centroids. G+H) Longitudinal analysis of
512 microbial diversity, depicted through Shannon diversity and Simpson evenness indices, shows a
513 reduction in both measures within the first-year post-transplantation for patients undergoing
514 rejection. Vertical red bars indicate individual rejection events over time, coinciding with alterations
515 in microbial diversity.

516

517 **Figure 2. Microbiome alteration precede kidney transplant rejection.** Patients with available fecal
518 samples prior to kidney rejection (Rejection group) for propensity score matched (1:2) to patients
519 without kidney rejection (Non-Rejection group). A) Plasma creatinine levels are depicted over time,
520 displaying a consistent increase within the first year post-transplant in patients who experienced
521 graft rejection (red), with these elevated levels persisting at follow-up. Vertical red bars indicate
522 individual rejection events over time. B) Analysis of minimum creatinine levels before and after
523 sampling, along with the time taken to reach the first. C) Gut microbial communities of the two
524 groups based on Bray-Curtis dissimilarity, demonstrate clear separation, with the rejection group

525 (red circles) showing distinct clustering from the non-rejection group (blue circles). Squares
526 represent the centroids of the groups. D) Microbial diversity metrics, including number of detected
527 OTUs, Shannon diversity, and Simpson evenness. E) Differences in microbial taxa between groups,
528 highlighting a decrease in short-chain fatty acid (SCFA)-producing bacteria in the rejection group and
529 an enrichment of genera commonly elevated in chronic kidney disease (CKD) and disease conditions.
530 Bacteria are shown in a phylogenetic tree where green lineages represent bacteria depleted and
531 pink bacteria enriched in patients with kidney rejection F) Differential abundance analysis of
532 bacterial genera, with significant changes identified between non-rejection and rejection groups.
533 Cliff's Delta values indicate the direction and extent of these differences. Blue dots show genera
534 increased in the non-rejection group and red increased in the rejection group.

535

536 **Figure 3. Fecal short-chain fatty acid production potential is reduced before kidney transplant**
537 **rejection.** Patients with available fecal samples prior to kidney rejection (Rejection group) for
538 propensity score matched (1:2) to patients without kidney rejection (Non-Rejection group).
539 Inference of functional data from taxonomic data using PICRUSt2 and mapping to pathways using
540 GOMixer. A) Clustering of kidney transplant recipients based on the presence (red circles) or absence
541 (blue circles) of graft rejection, illustrating differences in microbiome-derived functional potential.
542 Squares represent centroids. B) Functional pathways highlight an increase in proteolytic
543 fermentation and reactive nitrogen and oxygen species production pathways in patients who
544 experienced graft rejection (red). Non-rejection samples show enhanced pathways related to sugar
545 and polysaccharide metabolism, and mucus degradation (blue). C) Heatmap shows all 54 significant
546 GOMixer modules, with pink indicating high predicted abundances and green representing low
547 abundances across the 92 patients, divided into non-rejection and rejection. Blue dots denote
548 negative log₂ fold changes, indicating enhanced modules in non-rejection samples compared to

549 rejection samples, while red dots represent positive log₂ fold changes, signifying an increase in
550 patients experiencing graft rejection.

551

552 **Figure 4. Decreased abundance of short-chain fatty acid producing enzymes in the microbiome**
553 **before kidney transplant rejection.** Patients with available fecal samples prior to kidney rejection
554 (Rejection group) for propensity score matched (1:2) to patients without kidney rejection (Non-
555 Rejection group). A) Bacterial nutrient metabolism leading to SCFA, specifically butyrate and
556 propionate, production. Key bacterial enzymes highlighted in red. B) Abundance of bacterial
557 enzymes for SCFA production were assessed by qPCR from fecal DNA and normalized to 16s content.
558 While *bcd* was not significantly altered *but* and *mmdA* showed lower abundance in fecal samples
559 from patients with subsequent kidney rejection compared to those without rejection.

560

561 **Figure 5. Microbiome composition normalizes post-kidney transplant rejection.** Patients with
562 available fecal samples (sample 1) prior to kidney rejection (Rejection group) and sample 2 90-1000
563 days post-rejection were analyzed. Propensity score matched patients without kidney rejection
564 (Non-Rejection group) with two comparable samples were included as controls. A) Principal
565 Coordinates Analysis (PCoA) of microbiome samples based on Bray-Curtis dissimilarity demonstrates
566 a shift in the microbiome composition of rejection patients (red to purple) towards the non-rejection
567 group (blue) over time, suggesting a post-rejection stabilization. Squares represent centroids. B)
568 Microbial diversity measured by the number of detected OTU, Shannon diversity, and Simpson
569 evenness. C) Heatmap comparison of genus-level alterations between pre- and post-rejection
570 samples reveals significant directional changes in microbial populations after a rejection event,
571 contrasting with the stable profiles observed in non-rejection controls. Pre-rejection comparison
572 taken from Figure 3F. Asterisks indicate significance levels: FDR < 0.1 * FDR < 0.01 ** FDR < 0.001 ***.
573 Confounded signals are shown as circles. Effect size is shown as Cliffs delta with pink enriched and

574 green depleted. D) Boxplots show shifts at the genus level, of short-chain fatty acid producers,
575 *Blautia* and *Faecalibacterium*, and disease-associated genera, *Fusobacterium* and *Streptococcus*.

576

577 **Figure 6. Microbiome composition in kidney rejection partly mirrors CKD-related microbiome**
578 **alterations.** Correlation between CKD microbial signatures and kidney transplant rejection preceding
579 signatures. A) Scatter plot indicating the correlation between the microbial signatures observed
580 before kidney transplant (KT) rejections and those seen in chronic kidney disease (CKD) patients,
581 suggesting shared alterations. Dashed line indicates perfect overlap of effect sizes. B) Log
582 transformed rarefied abundance of key SCFA-producing genera (*Blautia* and *Faecalibacterium*) and
583 disease-associated genera (*Streptococcus* and *Fusobacterium*) across healthy controls (HC), CKD
584 patients, and KT recipients preceding graft rejection or without graft rejection (propensity-score
585 matched). C) Abundance of bacterial taxa involved in butyrate and propionate production between
586 HC and CKD patients, reflecting a decrease in these beneficial taxa in CKD.

587 References

- 588 1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. *Lancet*. Mar 25
589 2017;389(10075):1238-1252. doi:10.1016/S0140-6736(16)32064-5
- 590 2. Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. *N Engl*
591 *J Med*. Aug 19 2021;385(8):729-743. doi:10.1056/NEJMra2014530
- 592 3. Cooper JE. Evaluation and Treatment of Acute Rejection in Kidney Allografts. *Clin J Am Soc*
593 *Nephrol*. Mar 6 2020;15(3):430-438. doi:10.2215/CJN.11991019
- 594 4. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell*. Mar 27
595 2014;157(1):121-141. doi:10.1016/j.cell.2014.03.011
- 596 5. Belkaid Y, Harrison OJ. Homeostatic Immunity and the Microbiota. *Immunity*. Apr 18
597 2017;46(4):562-576. doi:10.1016/j.immuni.2017.04.008
- 598 6. Behrens F, Bartolomaeus H, Wilck N, Holle J. Gut-immune axis and cardiovascular risk in
599 chronic kidney disease. *Clin Kidney J*. Jan 2024;17(1):sfad303. doi:10.1093/ckj/sfad303
- 600 7. Schlender J, Behrens F, McParland V, et al. Bacterial metabolites and cardiovascular risk in
601 children with chronic kidney disease. *Mol Cell Pediatr*. Oct 22 2021;8(1):17. doi:10.1186/s40348-021-
602 00126-8
- 603 8. Holle J, Bartolomaeus H, Lober U, et al. Inflammation in Children with CKD Linked to Gut
604 Dysbiosis and Metabolite Imbalance. *J Am Soc Nephrol*. Dec 2022;33(12):2259-2275.
605 doi:10.1681/ASN.2022030378
- 606 9. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids,
607 regulate colonic Treg cell homeostasis. *Science*. Aug 2 2013;341(6145):569-573.
608 doi:10.1126/science.1241165
- 609 10. Swarte JC, Douwes RM, Hu S, et al. Characteristics and Dysbiosis of the Gut Microbiome in
610 Renal Transplant Recipients. *J Clin Med*. Feb 1 2020;9(2)doi:10.3390/jcm9020386
- 611 11. Lee JR, Magruder M, Zhang L, et al. Gut microbiota dysbiosis and diarrhea in kidney
612 transplant recipients. *Am J Transplant*. Feb 2019;19(2):488-500. doi:10.1111/ajt.14974
- 613 12. Fricke WF, Maddox C, Song Y, Bromberg JS. Human microbiota characterization in the course
614 of renal transplantation. *Am J Transplant*. Feb 2014;14(2):416-427. doi:10.1111/ajt.12588
- 615 13. Swarte JC, Li Y, Hu S, et al. Gut microbiome dysbiosis is associated with increased mortality
616 after solid organ transplantation. *Sci Transl Med*. Aug 31 2022;14(660):eabn7566.
617 doi:10.1126/scitranslmed.abn7566
- 618 14. Lei YM, Chen L, Wang Y, et al. The composition of the microbiota modulates allograft
619 rejection. *J Clin Invest*. Jul 1 2016;126(7):2736-2744. doi:10.1172/JCI85295
- 620 15. Sato Y, Yanagita M. Immunology of the ageing kidney. *Nature reviews Nephrology*. Oct
621 2019;15(10):625-640. doi:10.1038/s41581-019-0185-9
- 622 16. Wilck N, Matus MG, Kearney SM, et al. Salt-responsive gut commensal modulates TH17 axis
623 and disease. *Nature*. Nov 30 2017;551(7682):585-589. doi:10.1038/nature24628
- 624 17. Bartolomaeus H, Balogh A, Yakoub M, et al. Short-Chain Fatty Acid Propionate Protects From
625 Hypertensive Cardiovascular Damage. *Circulation*. Mar 12 2019;139(11):1407-1421.
626 doi:10.1161/CIRCULATIONAHA.118.036652
- 627 18. Wu H, Singer J, Kwan TK, et al. Gut Microbial Metabolites Induce Donor-Specific Tolerance of
628 Kidney Allografts through Induction of T Regulatory Cells by Short-Chain Fatty Acids. *J Am Soc*
629 *Nephrol*. Jun 1 2020;doi:10.1681/ASN.2019080852
- 630 19. Singer J, Li YJ, Ying T, et al. Protocol for a pilot single-centre, parallel-arm, randomised
631 controlled trial of dietary inulin to improve gut health in solid organ transplantation: the DIGEST
632 study. *BMJ Open*. 2021;11(4)
- 633 20. Sawitzki B, Harden PN, Reinke P, et al. Regulatory cell therapy in kidney transplantation (The
634 ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A
635 trials. *Lancet*. May 23 2020;395(10237):1627-1639. doi:10.1016/S0140-6736(20)30167-7

- 636 21. Karch A, Schindler D, Kuhn-Stein A, et al. The transplant cohort of the German center for
637 infection research (DZIF Tx-Cohort): study design and baseline characteristics. *Eur J Epidemiol*. Feb
638 2021;36(2):233-241. doi:10.1007/s10654-020-00715-3
- 639 22. *Deutsche Stiftung Organtransplantation (German Organ Procurement Organization).*
640 *Nierentransplantation: Grafiken zum Tätigkeitsbericht 2022 nach § 11 Abs. 5 TPG*. 2022.
- 641 23. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of
642 kidney transplant recipients: a summary. *Kidney Int*. Feb 2010;77(4):299-311.
643 doi:10.1038/ki.2009.377
- 644 24. Ho DE, Imai K, King G, Stuart EA. Matching as Nonparametric Preprocessing for Reducing
645 Model Dependence in Parametric Causal Inference. *Political Analysis*. 2007;15(3):199-236.
646 doi:10.1093/pan/15(3)199
- 647 25. Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): Updates on
648 and clarification of criteria for T cell- and antibody-mediated rejection. *Am J Transplant*. Sep
649 2020;20(9):2318-2331. doi:10.1111/ajt.15898
- 650 26. Ren Z, Fan Y, Li A, et al. Alterations of the Human Gut Microbiome in Chronic Kidney Disease.
651 *Adv Sci (Weinh)*. Oct 2020;7(20):2001936. doi:10.1002/adv.202001936
- 652 27. Lahti L, Sudarshan S. microbiome R package. <http://microbiome.github.io>
- 653 28. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysis and
654 Graphics of Microbiome Census Data. *PLOS ONE*. 2013;8(4):e61217.
655 doi:10.1371/journal.pone.0061217
- 656 29. Oksanen J, Blanchet FG, Kindt R, et al. Community ecology package. *R package version*.
657 2013;2(0):321-326.
- 658 30. Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, et al. Combinatorial, additive and
659 dose-dependent drug-microbiome associations. *Nature*. Dec 2021;600(7889):500-505.
660 doi:10.1038/s41586-021-04177-9
- 661 31. Chen C-Y, L̄ber U, Forslund SK. LongDat: an R package for covariate-sensitive longitudinal
662 analysis of high-dimensional data. *Bioinformatics Advances*. 2023;doi:10.1093/bioadv/vbad063
- 663 32. Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome functions.
664 *Nature Biotechnology*. 2020/06/01 2020;38(6):685-688. doi:10.1038/s41587-020-0548-6
- 665 33. Darzi Y, Falony G, Vieira-Silva S, Raes J. Towards biome-specific analysis of meta-omics data.
666 *ISME J*. May 2016;10(5):1025-1028. doi:10.1038/ismej.2015.188
- 667 34. Notting F, Pirovano W, Sybesma W, Kort R. The butyrate-producing and spore-forming
668 bacterial genus Coprococcus as a potential biomarker for neurological disorders. *Gut Microbiome*.
669 2023;4:e16. e16. doi:10.1017/gmb.2023.14
- 670 35. Zhang J, Song L, Wang Y, et al. Beneficial effect of butyrate-producing Lachnospiraceae on
671 stress-induced visceral hypersensitivity in rats. *J Gastroenterol Hepatol*. Aug 2019;34(8):1368-1376.
672 doi:10.1111/jgh.14536
- 673 36. Kasahara K, Krautkramer KA, Org E, et al. Interactions between Roseburia intestinalis and
674 diet modulate atherosclerosis in a murine model. *Nat Microbiol*. Dec 2018;3(12):1461-1471.
675 doi:10.1038/s41564-018-0272-x
- 676 37. Lenoir M, Martín R, Torres-Maravilla E, et al. Butyrate mediates anti-inflammatory effects of
677 Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3. *Gut Microbes*. Nov 9
678 2020;12(1):1-16. doi:10.1080/19490976.2020.1826748
- 679 38. Reichardt N, Duncan SH, Young P, et al. Phylogenetic distribution of three pathways for
680 propionate production within the human gut microbiota. *ISME J*. Jun 2014;8(6):1323-1335.
681 doi:10.1038/ismej.2014.14
- 682 39. Sayols-Baixeras S, Dekkers KF, Baldanzi G, et al. Streptococcus Species Abundance in the Gut
683 Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort.
684 *Circulation*. 2023;148(6):459-472. doi:doi:10.1161/CIRCULATIONAHA.123.063914
- 685 40. Gupta VK, Kim M, Bakshi U, et al. A predictive index for health status using species-level gut
686 microbiome profiling. *Nat Commun*. Sep 15 2020;11(1):4635. doi:10.1038/s41467-020-18476-8

- 687 41. Stanisic D, Jeremic N, Singh M, Pushpakumar S, Mokshagundam SPL, Tyagi SC.
688 Porphyromonas gingivalis induces cardiovascular dysfunction. *Can J Physiol Pharmacol*. Aug 1
689 2023;101(8):413-424. doi:10.1139/cjpp-2022-0392
- 690 42. Vieira-Silva S, Falony G, Darzi Y, et al. Species-function relationships shape ecological
691 properties of the human gut microbiome. *Nat Microbiol*. Jun 13 2016;1(8):16088.
692 doi:10.1038/nmicrobiol.2016.88
- 693 43. Wang X, Yang S, Li S, et al. Aberrant gut microbiota alters host metabolome and impacts
694 renal failure in humans and rodents. *Gut*. Dec 2020;69(12):2131-2142. doi:10.1136/gutjnl-2019-
695 319766
- 696 44. Stubbs JR, House JA, Ocque AJ, et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and
697 Correlates with Coronary Atherosclerosis Burden. *J Am Soc Nephrol*. Jan 2016;27(1):305-313.
698 doi:10.1681/ASN.2014111063
- 699 45. Opdebeeck B, Maudsley S, Azmi A, et al. Indoxyl Sulfate and p-Cresyl Sulfate Promote
700 Vascular Calcification and Associate with Glucose Intolerance. *J Am Soc Nephrol*. May
701 2019;30(5):751-766. doi:10.1681/ASN.2018060609
- 702 46. Holle J, Kirchner M, Okun J, et al. Serum indoxyl sulfate concentrations associate with
703 progression of chronic kidney disease in children. *PLoS One*. 2020;15(10):e0240446.
704 doi:10.1371/journal.pone.0240446
- 705 47. Gacesa R, Kurilshikov A, Vich Vila A, et al. Environmental factors shaping the gut microbiome
706 in a Dutch population. *Nature*. 2022/04/01 2022;604(7907):732-739. doi:10.1038/s41586-022-
707 04567-7
- 708 48. Avery EG, Bartolomaeus H, Rauch A, et al. Quantifying the impact of gut microbiota on
709 inflammation and hypertensive organ damage. *Cardiovasc Res*. Jul 29 2022;doi:10.1093/cvr/cvac121
- 710 49. Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among the gut microbiome,
711 short-chain fatty acids and metabolic diseases. *Nat Genet*. Apr 2019;51(4):600-605.
712 doi:10.1038/s41588-019-0350-x
- 713 50. Kim CH. Complex regulatory effects of gut microbial short-chain fatty acids on immune
714 tolerance and autoimmunity. *Cellular & Molecular Immunology*. 2023/04/01 2023;20(4):341-350.
715 doi:10.1038/s41423-023-00987-1
- 716 51. Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial
717 communities using 16S rRNA marker gene sequences. *Nature Biotechnology*. 2013/09/01
718 2013;31(9):814-821. doi:10.1038/nbt.2676
- 719 52. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote
720 peripheral regulatory T-cell generation. *Nature*. Dec 19 2013;504(7480):451-455.
721 doi:10.1038/nature12726
- 722 53. Wu H, Singer J, Kwan TK, et al. Gut Microbial Metabolites Induce Donor-Specific Tolerance of
723 Kidney Allografts through Induction of T Regulatory Cells by Short-Chain Fatty Acids. *Journal of the*
724 *American Society of Nephrology*. 2020;31(7)
- 725 54. Rangaswami J, Mathew RO, Parasuraman R, et al. Cardiovascular disease in the kidney
726 transplant recipient: epidemiology, diagnosis and management strategies. *Nephrology Dialysis*
727 *Transplantation*. 2019;34(5):760-773. doi:10.1093/ndt/gfz053
- 728 55. Lee JR, Muthukumar T, Dadhania D, et al. Gut microbial community structure and
729 complications after kidney transplantation: a pilot study. *Transplantation*. Oct 15 2014;98(7):697-
730 705. doi:10.1097/tp.0000000000000370
- 731 56. Wang J, Li X, Wu X, et al. Gut microbiota alterations associated with antibody-mediated
732 rejection after kidney transplantation. *Appl Microbiol Biotechnol*. Mar 2021;105(6):2473-2484.
733 doi:10.1007/s00253-020-11069-x

734









